{
  "@context": {
    "bioagents": "https://bio.agents/ontology/",
    "bsc": "http://bioschemas.org/",
    "bsct": "http://bioschemas.org/types/",
    "dct": "http://purl.org/dc/terms/",
    "edam": "http://edamontology.org/",
    "owl": "http://www.w3.org/2002/07/owl#",
    "rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
    "rdfs": "http://www.w3.org/2000/01/rdf-schema#",
    "sc": "http://schema.org/",
    "xsd": "http://www.w3.org/2001/XMLSchema#"
  },
  "@graph": [
    {
      "@id": "https://doi.org/10.3389/FGENE.2019.01378",
      "@type": "sc:CreativeWork"
    },
    {
      "@id": "https://bio.agents/pub2agents2020__osgbm",
      "@type": "sc:SoftwareApplication",
      "dct:conformsTo": "https://bioschemas.org/profiles/ComputationalAgent/0.6-DRAFT",
      "sc:additionalType": "Web application",
      "sc:applicationSubCategory": [
        {
          "@id": "edam:topic_3379"
        },
        {
          "@id": "edam:topic_3360"
        },
        {
          "@id": "edam:topic_3170"
        },
        {
          "@id": "edam:topic_3308"
        }
      ],
      "sc:citation": [
        "pubmed:32153627",
        "pmcid:PMC7046682",
        {
          "@id": "https://doi.org/10.3389/FGENE.2019.01378"
        }
      ],
      "sc:description": "An Online Consensus Survival Analysis Web Server for Glioblastoma.\n\nGlioblastoma (GBM) is the most common malignant tumor of the central nervous system. GBM causes poor clinical outcome and high mortality rate, mainly due to the lack of effective targeted therapy and prognostic biomarkers.",
      "sc:featureList": [
        {
          "@id": "edam:operation_3503"
        },
        {
          "@id": "edam:operation_2495"
        }
      ],
      "sc:name": "OSgbm",
      "sc:url": "http://bioinfo.henu.edu.cn/GBM/GBMList.jsp"
    }
  ]
}